Back to Journals » Drug Design, Development and Therapy » Volume 5

Review

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond

       
Total article views   HTML views PDF downloads Totals
37,074 Dovepress* 19,497+ 5,801 25,298
PubMed Central* 17,577 5,330 22,907
Totals 37,074 11,131 48,205
*Since 23 November 2011
+Since July 2016

View citations on PubMed Central and Google Scholar